These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16026359)

  • 1. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes.
    Leiter LA
    Diabet Med; 2005 Aug; 22(8):963-72. PubMed ID: 16026359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of beta-cell management in type 2 diabetes.
    Standl E
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.
    Walter H; Lübben G
    Drugs; 2005; 65(1):1-13. PubMed ID: 15610048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis.
    Decker M; Hofflich H; Elias AN
    Diabetes Obes Metab; 2008 Aug; 10(8):617-25. PubMed ID: 17645549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. beta-cell function and anti-diabetic pharmacotherapy.
    Del Prato S; Bianchi C; Marchetti P
    Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of thiazolidinediones in the management of type 2 diabetes: focus on ethnic minority populations.
    Umpierrez G; Dagogo-Jack S
    Ethn Dis; 2006; 16(1):51-7. PubMed ID: 16599348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents.
    Home PD; Pacini G
    Diabetes Obes Metab; 2008 Sep; 10(9):699-718. PubMed ID: 17825080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
    Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones in type 2 diabetes--have they lived up to expectations?
    Bhansali A; Modi P
    J Indian Med Assoc; 2005 Jun; 103(6):343-6. PubMed ID: 16225162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 diabetes, psoriasis and thiazolidinediones.
    Krentz AJ; Friedmann PS
    Int J Clin Pract; 2006 Mar; 60(3):362-3. PubMed ID: 16494655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.
    Lupi R; Del Prato S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S56-64. PubMed ID: 18640587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones.
    Edelman SV
    N Engl J Med; 2005 Jan; 352(2):205-7; author reply 205-7. PubMed ID: 15651124
    [No Abstract]   [Full Text] [Related]  

  • 17. Pioglitazone plus glimepiride: a promising alternative in metabolic control.
    Derosa G
    Int J Clin Pract Suppl; 2007 Jun; (153):28-36. PubMed ID: 17594391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Closing the gap between clinical research and clinical practice: can outcome studies with thiazolidinediones improve our understanding of type 2 diabetes?
    Goldstein BJ
    Int J Clin Pract; 2006 Jul; 60(7):873-83. PubMed ID: 16846404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
    Strowig SM; Raskin P
    Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.